Company Profile

AtaGenix Laboratories Co., Ltd. is a contract research organization (CRO) specializing in custom antibody and recombinant protein solutions for research and drug development. Founded in 2011 within the Wuhan National Bio-Industry Base, AtaGenix operates as the designated Antibody Discovery and Screening Public Service Platform, serving global pharmaceutical, biotech, and academic partners with 15 years of project delivery experience.

2011

Founded in Wuhan

4,700 m²

Total Facility Area

Expression Platforms

>90%

Project Success Rate*

Facility & Infrastructure

Located in Wuhan National Bio-Industry Base (Optics Valley), the AtaGenix facility covers 4,700 m², including an 800 m² GMP-grade cell culture room and a 100 m² sterile endotoxin-free purification laboratory, with equipment investment exceeding 20 million RMB. Operations conform to ISO 9001:2015 and ISO 13485:2016 (RUO scope).

Three Integrated Service Platforms

Life Sciences Platform

Five protein expression systems (mammalian HEK293/CHO, E. coli, Bacillus subtilis, yeast, insect cell/BEVS) supporting recombinant protein expression, molecular construction, purification, structural analysis, recombinant antibody expression, and mouse/rabbit monoclonal antibody production.

Antibody Drug Discovery Platform

Single B cell (Xten™ Mab), hybridoma, and phage display technologies. Proprietary libraries include camelid VHH nanobody, rabbit naïve, and mouse naïve libraries. Multi-species library construction and screening (mouse, rabbit, chicken, pig, cat, dog). Antibody engineering: humanization, affinity maturation, bispecific development.

Diagnostic Material Development Platform

Open automated chemiluminescence platform that shortens R&D cycles, reduces development costs, and provides diagnostic core material development services including antigen/antibody pairs for immunoassay kit manufacturing.

Proprietary Technologies

AtaGenix has developed a portfolio of proprietary technologies including the XtenCHO™ high-density mammalian cell expression system (200–400 mg/L, up to 1 g/L for antibodies), MHC-peptide complex expression, multimer directional expression, production-scale stable cell line construction (CHO-K1, DG44 with G418/DHFR/GS selection), and the Xten™ Mab single B cell antibody discovery platform. These technologies have been validated across tens of thousands of delivered projects.

Product Portfolio

Beyond custom services, AtaGenix offers a comprehensive catalog through its research reagent brand abinScience, featuring 35,000+ products including recombinant antibodies, proteins, ELISA assay kits, research biosimilars, tool enzymes, and stable cell lines — covering 9,000+ unique targets across major research areas.

Clients & Collaborations

AtaGenix partners with global pharmaceutical companies, international diagnostic organizations, leading agricultural biotech firms, and top-tier academic medical centers across Asia, Europe, and North America. Tens of thousands of custom R&D projects have been successfully delivered, spanning drug discovery, diagnostic development, and translational medicine. Service reagents have been cited in publications in Nature Communications, Advanced Materials, Immunity, Advanced Science, Nature Microbiology, and other peer-reviewed journals.

*Success rate based on projects meeting pre-agreed acceptance criteria (past 3 years). ISO 13485 scope: RUO products; clinical/GMP scope available upon request.

Ready to discuss your next antibody or protein project? AtaGenix scientists will design a tailored approach for your specific target and application.

Talk to Technical Support

Response within 24 hours